Search Results
Oct 16, 2025, 08:35 ET Unixell Biotech reported a case study of UX-DA001, an iPSC-derived autologous cell therapy for Parkinson Diseases at MDS Congress 2025
(PD) and other neurological disorders, announced positive 6-month follow-up data from the first patient in its phase 1 clinical trial for UX-DA001, an iPSC-derived autologous cell therapy for PD. These data were presented on October 8th at the International Congress of Parkinson's Disease and Movement Disorders
More news about: UniXell Biotechnology
Oct 15, 2025, 10:00 ET Nikon Small World Honors 51st Annual Photomicrography Competition
WhittakerNational Institutes of HealthNational Institute of Neurological Disorders and StrokeBethesda, Maryland, USAiPSC-derived sensory neurons labelled to show tubulin and actinConfocal, Fluorescence, Image Stacking10X (Objective Lens Magnification)
More news about: Nikon Instruments Inc.
Oct 14, 2025, 09:00 ET iQure Pharma Enters into Research Collaboration with the University of Padova
and cellular techniques for investigating the signaling pathways involved in the disease, and in validating findings in complex systems such as human iPSC-derived cells as well as in vivo models. In recent years, she has deepened her research on the role of glial cells, in particular astrocytes, in Parkinson's
More news about: iQure Pharma Inc.
Oct 13, 2025, 09:00 ET iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
"Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both the NMPA and the FDA to treat Parkinson's disease (PD). Recently, NouvNeu001 Phase I clinical data were presented
More news about: iRegene therapeutics
Oct 09, 2025, 07:52 ET Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models
tolerated and highly selective for ERβ, with no ERα-linked safety concerns observed. In addition, K102 promoted oligodendrocyte maturation in human iPSC-derived cells, reinforcing translational relevance. Study highlights (Preclinical)
More news about: Cadenza Bio, Inc.
Oct 08, 2025, 09:05 ET SIG SAUER Congratulates Mason Lane on his World Championship Win
ammunition, is proud to congratulate Team SIG member Mason Lane on his incredible success at the 2025 International Practical Shooting Confederation (IPSC) Handgun World Shoot held at the Frontier Shooting range in Stilfontein, South Africa. Mason walked away champion of the men's overall production division
More news about: SIG SAUER, Inc.
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
Collaborative research with AGC Inc. on the expansion and functional evaluation of iPSC-HSPCs Ongoing evaluations of our HSC expansion platform by global pharmaceutical and biotech companies
More news about: Celaid Therapeutics Inc.
Sep 30, 2025, 08:30 ET Klotho Neurosciences Signs Letter of Intent to Acquire Select Assets from Turn Biotechnologies, Anchored by $300 Million Global Pharma Partnership
it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement,
More news about: Klotho Neurosciences, Inc.
Sep 29, 2025, 14:15 ET Cell X Technologies and BioLamina enter a collaboration to advance standardization in iPSC-based therapeutics
isoforms (both research-use-only and GMP-compatible formulations) into predefined and optimized automated workflows, the partnership seeks to streamline iPSC culture and differentiation while minimizing operator-dependent variability. "Cell X Technologies is committed to advancing automation
More news about: Cell X Technologies, Inc
Sep 25, 2025, 09:03 ET Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson's Disease
highest quality personalized cells for the patient.Therapeutic Platform. ANPD001 is an autologous induced pluripotent stem cell (iPSC)-derived DANPC therapy. It is a personalized regenerative cell therapy that uses a patient's own cells, avoiding immune rejection and offering tailored
More news about: Aspen Neuroscience, Inc.
Sep 16, 2025, 07:30 ET Yasir Al-Wakeel Appointed CEO of Vesalius Therapeutics and CEO-Partner of Flagship Pioneering
respond favorably to treatments by targeting novel points of intervention. Using large-scale human genetics, genomics, induced pluripotent stem cell (iPSC) models, and artificial intelligence, the company's Physio-Logic platform genetically validates novel molecular targets to identify causal drivers of
More news about: Flagship Pioneering
Sep 15, 2025, 10:01 ET Made Scientific and Basilard BioTech Announce Technology Partnership to Advance Ex Vivo Gene Delivery for T Cell and iPSC Therapies
state-of-the-art GMP manufacturing facility in Princeton, NJ, to validate and scale the Celletto™ platform across T cell, iPSC processes, and other cell substrates in the future. "We look forward to collaborating with Made Scientific to demonstrate the transformative,
More news about: Made Scientific, Inc.
Sep 12, 2025, 09:30 ET Shineco (SISI) Ignites Growth: $8.7M Tech Deal & Major Singapore Alliance Unleash Dual Engines
2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances. Its subsidiary, Xi'an Dong'ao Health Management Co., Ltd. ("Dong'ao Health"), has
More news about: Shineco,Inc.
Sep 11, 2025, 19:30 ET Companhia Brasileira de Cartuchos realiza Campeonato Expresso 2025
se descobrem. Percebem que têm potencial para competir em níveis maiores, em rankings mais altos, e acabam se identificando com modalidades como o IPSC, o Tiro ao Prato, o Tiro de Precisão ou em Movimento. É justamente esse equilíbrio entre diversão, baixo custo e seriedade, no qual seguimos todos os
More news about: Companhia Brasileira de Cartuchos
Sep 11, 2025, 08:00 ET PhenoVista Biosciences and Carolina Molecular Announce Partnership to Extend Multi-omic Data Access to Clients
models and the latest high-content imaging technologies and data-analysis capabilities. Their diverse repertoire includes working with primary cells, iPSC-derived neurons and glia, and client-engineered lines in a variety of formats. About Carolina Molecular Carolina Molecular is a
More news about: Carolina Molecular
Sep 10, 2025, 09:30 ET Shineco Achieves Mass Production of High-Purity Physical Phospholipids, Breaking Foreign Monopoly and Unlocking Innovation Across Industries
10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd., has successfully achieved large-scale production
More news about: Shineco,Inc.
Sep 09, 2025, 09:00 ET iRegene Therapeutics Secures Series B+ Financing Following FDA Fast Track Designation for its Flagship Product NouvNeu001
August 2025, NouvNeu001 received Fast Track Designation (FTD) from the U.S. FDA, making it the world's first allogeneic iPSC-derived cell therapy for Parkinson's disease to achieve this milestone. This round builds on a series of sizable financings completed in recent
More news about: iRegene therapeutics
Sep 03, 2025, 05:27 ET Making Hope Possible: American Parkinson Disease Association Supports Researchers With $4.04 Million in New Funding
Matthew Keeney, PhD – Brigham and Women's Hospital | Project: Dissecting the Impact of PD-relevant Stressors on RNA-binding Protein Biology in Tractable iPSC Synucleinopathy Models
More news about: American Parkinson Disease Association, Inc.
Aug 29, 2025, 01:23 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
al[24] Rescue of neuronal activity in iPSC-derived STXBP1 in vitro disease models using viral vectors
More news about: UCB
Aug 29, 2025, 01:15 ET UCB presents latest research and clinical advancement across leading epilepsy portfolio at International Epilepsy Congress
al[24] Rescue of neuronal activity in iPSC-derived STXBP1 in vitro disease models using viral vectors
More news about: UCB
Aug 28, 2025, 10:00 ET Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs
cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid's proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC's iPSC technology to accelerate robust and scalable expansion of iPSC-HSPCs. In this project, Celaid's human HSC
More news about: Celaid Therapeutics Inc.
Aug 27, 2025, 06:30 ET Shineco (NASDAQ: SISI) & BICC: From "Tech On-Chain" to "Global Redeemability"--RWA Ecosystem Takes Off for Long-Term Growth
Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly
More news about: Shineco,Inc.
Aug 20, 2025, 06:30 ET Shineco Unveils World's First On-Chain Cell Asset Tokenization Platform; Strategic Acquisition Expands Global Blockchain-Biotech Network
20, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure
More news about: Shineco,Inc.
Aug 13, 2025, 06:30 ET Shineco Establishes Biological Cell Digital Division to Integrate Biological Cell Assets and Blockchain Technology
2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment
More news about: Shineco,Inc.
Aug 12, 2025, 11:00 ET Gameto's $44M Series C to Help Redefine Reproductive Care, as First Patients Recruited for Pivotal Stem Cell Phase 3 Trial
first induced pluripotent stem cell (iPSC)-derived therapy to reach late-stage clinical development in the United States, a long-awaited milestone following Shinya Yamanaka receiving the Nobel Prize for iPSC technology in 2012. Gameto's novel
More news about: Gameto